Clinical trials: Pseudomonas Infections
Covid19, Bacteremia
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
Phage Treatment in Covid-19 Patients with Bacterial Co-Infections
- Conditions
- Covid19, Bacteremia, Septicemia, Acinetobacter Baumannii Infection
- Trial name
- NCT04636554
- Testing
- Phage Therapy
- Sponsor
- Adaptive Phage Therapeutics, Inc.
Wound Infection
Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients
The central aim of this trial is to investigate the safety and tolerability of Phage Cocktail-SPK as an adjunct to standard therapy for the prevention and treatment of burns susceptible to infection/or infected by S. aureus, P.
- Trial name
- NCT04323475
- Testing
- Bacteriophage cocktail spray, Xeroform
- Volunteers
- 12 people
- Sponsor
- Precisio Biotix Therapeutics, Inc.
Metastatic Breast Cancer
Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)
The progression free survival could be prolonged adding pseudomonas aeruginosa to monotherapy capecitabine.
- Trial name
- NCT01380808
- Testing
- capecitabine and pseudomonas aeruginosa combination
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Hematologic Neoplasms, Neutropenia
Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients
Patients with hematological malignancies receive highly myelotoxic chemotherapy regimens that cause periods of severe myelosuppression, which places them at high risk of developing bacteremia.
- Trial name
- NCT06422533
- Testing
- Ceftolozane/tazobactam, Piperacillin/tazobactam
- Where
- Mexico
- Volunteers
- 226 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Cystic Fibrosis
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
The purpose of this study is to confirm and extend the Phase 1-2 KB001 findings of an airway anti-inflammatory effect in CF individuals with chronic Pseudomonas aeruginosa (Pa) airway infection.
- Trial name
- KB001-A (NCT01695343)
- Testing
- KB001-A
- Where
- 67 sites in United States, Australia and 2 more
- Volunteers
- 182 people
- Sponsor
- Humanigen, Inc.
Bronchiectasis
Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis
Chronic airways infection with Pseudomonas aeruginosa (PA) is associated with increased frequency of exacerbations, deterioration in quality of life and increased mortality in adult patients with bronchiectasis.
- Trial name
- ANTEIPA (NCT06368804)
- Testing
- Antibiotic monotherapy treatment and follow-up, Antibiotic bitherapy treatment and follow-up
- Where
- 18 sites in France
- Volunteers
- 196 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Cystic Fibrosis
Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
A major factor in the respiratory health of cystic fibrosis (CF) patients is acquisition of chronic Pseudomonas (P.) aeruginosa infections. The infection rate with P.
- Trial name
- NCT03905642
- Testing
- Arikayce™
- Where
- 11 sites in Belgium, Hungary and 5 more
- Volunteers
- 49 people
- Sponsor
- Insmed Incorporated
Wound, Chronic Leg Ulcer
Positive Predictive Value (PPV) of Pseudomonas Aeruginosa
This is a non-randomized, single-blind post market clinical follow-up study for which 65 patients will be imaged at Rouge Valley Centenary Hospital (Scarborough and Rouge Hospital) who present with a chronic wound and are…
- Conditions
- Wound, Chronic Leg Ulcer, Wound Contamination
- Trial name
- NCT03290690
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- MolecuLight Inc.
Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections
PMT for MDRO Decolonization
This is a randomized, open label, comparative Phase II trial being conducted to determine whether fecal microbiota transplant using Penn Microbiome Therapy (PMT) products helps standard therapy eradicate antibiotic-resistant…
- Conditions
- Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa, VRE Infection
- Trial name
- NCT05632315
- Testing
- PMT
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Pennsylvania
Cystic Fibrosis
Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life
The goal of this study is characterize the changes in bacterial diversity of the upper respiratory tracts of infants with cystic fibrosis (CF).
- Trial name
- NCT00977158
- Testing
- Throat Swab
- Where
- 2 sites in United States
- Sponsor
- Tufts Medical Center
Pseudomonas Infections, Pseudomonas Aeruginosa
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality.
- Trial name
- NCT03510351
- Testing
- Ceftolozane-Tazobactam
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Temple University
Cystic Fibrosis
Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa
The primary objective of this study is to evaluate the safety and tolerability of a single dose of KB001 in Cystic Fibrosis patients infected with Pseudomonas aeruginosa (Pa)
- Trial name
- NCT00638365
- Testing
- KB001
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Humanigen, Inc.
Pseudomonas Aeruginosa Pneumonia
Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia caused by P. aeruginosa.
- Trial name
- NCT03027609
- Testing
- AR-105
- Where
- 111 sites in United States, Australia and 15 more
- Volunteers
- 158 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
Cystic Fibrosis
Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000
The purpose of this study is to describe two cohorts of cystic fibrosis patients treated in 2 different decades in terms of FEV1 (Forced Expiratory Volume in one second) maintenance.
- Trial name
- MAESTRALE (NCT01651455)
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Hairy Cell Leukemia
LMB-2 to Treat Hairy Cell Leukemia
Background: About 80% of patients with hairy cell leukemia (HCL) have tumor cells that have a protein on their surface called cluster of differentiation 25 (CD25).
- Trial name
- NCT00321555
- Testing
- Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma
RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells.
- Trial name
- NCT00074334
- Testing
- TGFa-PE38 immunotoxin, conventional surgery
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pediatric Brain Tumor Consortium
Pseudomonas Aeruginosa Meningitis
Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration
Meningitis is an infection where morbidity and mortality depend on the delay of the initial treatment for a good prognostic. The antibiotherapy rapidity allows to decrease the mortality.
- Trial name
- NCT00752882
- Testing
- ceftazidime
- Volunteers
- 24 people
- Sponsor
- University Hospital, Clermont-Ferrand
Bronchiectasis With Pseudomonas Aeruginosa Colonization
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
- Trial name
- CLEAR (NCT07088926)
- Testing
- AZD0292
- Where
- 186 sites in United States, Argentina and 23 more
- Volunteers
- 435 people
- Sponsor
- AstraZeneca
Surgical Site Infection, Staphylococcus Aureus Infection
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S.
- Conditions
- Surgical Site Infection, Staphylococcus Aureus Infection, Pseudomonas Aeruginosa Infection, Bacterial Infections
- Trial name
- NCT06319235
- Testing
- IMP
- Where
- Czechia
- Volunteers
- 52 people
- Sponsor
- MB PHARMA s.r.o.